Try our mobile app
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File Number) |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number,
including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 3, 2022, the board of directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (the “Company”) elected Craig B. Thompson, M.D. as a director. With the addition of Dr. Thompson, the Board has been expanded from 12 to 13 members. Dr. Thompson has also been appointed to serve on the Technology Committee of the Board. In accordance with the requirements of the New York Business Corporation Law, Dr. Thompson will hold office until the 2023 Annual Shareholder Meeting of the Company.
Dr. Thompson will receive compensation from the Company for his service as a director in accordance with the Company’s compensation practices for non-employee directors, as described under the caption “Compensation of Directors” in the Company’s definitive proxy statement filed on April 21, 2022.
There is no arrangement or understanding between Dr. Thompson and any other person pursuant to which he was selected as a director.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| REGENERON PHARMACEUTICALS, INC. | |
|
/s/ Joseph J. LaRosa |
|
| Joseph J. LaRosa | |
| Executive Vice President, General Counsel and Secretary | |
Date: October 3, 2022
